NCT04015661

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC

Induction Chemotherapy With Nab-paclitaxel and Nedaplatin Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Nasopharyngeal Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 92 (estimated)
• Sponsor: Fuzhou General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Nasopharyngeal carcinoma (NPC) is a malignant tumor that originates in nasopharyngeal epithelial cells. It is common in southern China and Southeast Asia, but the incidence rate is low in most parts of the world. According to the World Health Organization survey, 80% of nasopharyngeal carcinomas occur in China, with high incidence in southern China, as high as 30-50/100,000, such as Guangdong, Guangxi, Hunan, and Fujian. In 2015, Chinese cancer statistics showed that there were about 60,600 new cases of nasopharyngeal carcinoma in China, and the number of deaths was about 34,100. Radiation therapy is the main treatment for nasopharyngeal carcinoma. Early stage I and IIa achieved a 5-year survival rate (OS) of 90% and 84%, respectively . However, the treatment outcomes of most patients with locally advanced nasopharyngeal carcinoma are not ideal.

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Nab-paclitaxel	induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy

Timeline

• Start date: 2019-07-09
• Primary completion: 2020-12-01
• Completion: 2022-06-01
• First posted: 2019-07-11
• Last updated: 2019-07-11

Locations

1 site across 1 country: China